



Atty. Dkt. No. 028093-0113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vladimir SABETSKY

Title: ORAL INSULIN COMPOSITION
AND METHODS OF MAKING
AND USING THEREOF

Appl. No.: 10/792,376

Filing Date: 03/04/2004

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.


RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Respectfully submitted,

Date _____ 4/21/04

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Leon Radomsky
Attorney for Applicant
Registration No. 43,445

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: 4/21/04 APR 21 2004 <i>(use as many sheets as necessary)</i>				Application Number	10/792,376
Sheet	1	of	3	Filing Date	3/4/04
				First Named Inventor	Vladimir SABETSKY
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	028093-0113

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A14	Griffith L. Acta Mater. 48 (2000): 263-277	Y
	A15	Angelova N. and Hunkeler D., TIBTECH, 17 (1999): 409-421	Y
	A16	Tirrell M., Kokkoli E., Biesalski M., Surface Science 500 (2002): 61-83	Y
	A17	Madsen S., Moony D., PSTT 11 (2000): 381-384	Y

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 2). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/792,376
Date Submitted: 4/21/04				Filing Date	3/4/04
(use as many sheets as necessary)				First Named Inventor	Vladimir SABETSKY
Sheet	2	of	3	Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	028093-0113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A18	Eliaz R., Szoka F., Gene Therapy 9 (2002): 1230-1237	Y
	A19	Blain J.F., Maghni K., Pelletier S. and Sirois P. Inflamm. Res. 48 (1999): 386-392	Y
	A20	Crystallized carbohydrate spheres as a slow release matrix for biologically active substances, Ulf Schroder, Biomaterials 1984, Vol. 5 March	Y
	A21	Crytallized Carbohydrate Spheres for Slow Release and Targeting, Ulf Schroder, Methods in Enzymology, Vol. 12	Y
	A22	Surfactant-Free Preparation of Biodegradable Hydrogel Microspheres for Protein Release, Yasuhiko Tabata, et al., Journal of Bioactive and Compatible Polymers, Vol. 14-September 1999	Y
	A23	Partitioning in Aqueous Two-Phase Systems. A comprehensive bibliography in three parts: (1956-1984; 1985-1990; 1991-present) Part III: 1991-present Part II: 1985-1990	Y
	A24	Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres, A. Baranov, et al., Gene Therapy 6 (1999), 1406-1414	Y
	A25	Regulated insulin release from biodegradable dextran hydrogels containing poly(ethylene glycol), Kazuteru Moriyama, et al., Journal of Controlled Release 42 (1996) 237-248	Y
	A26	Lantus Prescribing Information – Aventis Pharmaceuticals (http://www.aventis-us.com/PIs/lantus_TXT.html visited 2/23/04	Y
	A27	Sephadex-based cell-affinity adsorbents: preparation and performance, Geert Besselink, et al, Biotechnol., Appl. Biochem. 35 (2002), 55-60	Y
	A28	Formation of dextran hydrogels by crystallization, R.J.H. Stenekes, et al., Biomaterials 22 (2001) 1891-0898	Y
	A29	Enhanced Loading and Activity Retention of Proteins in Hydrogel Delivery Systems, S.H. Gehrke, et al, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22 (1995), Controlled Release Society, Inc., p. 145-146	Y
	A30	Amidon GL, Lee HJ, Absorption of Peptide and Peptidomimetic Drugs, Ann. Rev. Pharmacol. Toxicol 1994; 34: 321-41	Y
	A31	Abstract, Pharmacological Management of Type 2 Diabetes Mellitus: rationale for rational use of insulin., Mayo Clin Proc. 2003 Apr; 78(4): 459-67, Chan JL, Abrahamson MJ, Mayo Clin Proc. 2003 Apr; 78(4):411-3	A

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/792,376
Date Submitted: 4/21/04				Filing Date	3/4/04
(use as many sheets as necessary)				First Named Inventor	Vladimir SABETSKY
Sheet	3	of	3	Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	028093-0113

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	A32	Abstract, Improvement of Transmucosal Absorption of Biologically Active Peptide Drugs, Akira Yamamoto, Department of Biopharmaceuticals, Kyoto Pharmaceutical University, Misasagi 8/31/2001		A
	A33	Abstract, 2002 American Diabetes Association Annual Meeting, Significant Hypoglycemic Effect of a Perorally-delivered Insulin in the Treatment of Streptozocin-induced Diabetic Rats, Frank K. Leung, Jiang Li, Lanqui Huang and Emily Leung.		A
	A34	Abstract, Oligopeptides as Potential Insulin Drug Delivery System, Raphael M. Ottenbrite, Rui Zhoa, Mamoru Haratake, Dept. of Chemistry, Virginia Commonwealth University, Richmond, VA		A
	A35	Abstract, Insulin loaded multilayer dextran sulfate/protamine microparticles Nadezda G. Balabushevich1, Gleb B. Sukhorukov2 and Natalia I. Larionova, 1 Department of Chemistry, Moscow State University, 119992 Russia, 2 Max-Planck Institute of Colloids and Interfaces, Golm/Potsdam, 14424, German.		A
	A36	Abstract, Insulin Containing Polyethylenimine-dextran Sulfate Nanoparticles, Int J. Pharm. 2003 Apr 14; 255(1-2):139-51, Tiyaboonchai W., Woiszwillo J., Sims RC, Middaugh CR, Dept. of Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, 2095 Constant Ave., Lawrence, KS 66047-3729 USA		A
	A37	Abstract, Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers, Pharm Res. 2003 Jan; 20(1):110-6., Forasker AB, Walczak RJ, Cohen MH, Bojarski TA, Grove CF, Swaan PW, The Ohio State University of Pharmacy, Division of Pharmaceutics, 500 West 12 th Ave., Columbus, OH 43210, USA		A
	A38	Abstract, Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats, J. Microencapsul. 2004 Jan-Feb; 21(1): 37-45, Qi R, Ping QN		A
	A39	Abstract, Preparation and characterization of enteric microspheres containing bovine insulin by a w/o/w emulsion solvent evaporation method, Chem Pharm Bull (Tokyo) 1998 Oct; 46(10): 1613-7, Nagareya N., Uchida T, Matsuyama K.		A
	A40	Abstract, Intestinal absorption of human insulin in pigs using delivery systems based on superporous hydrogel polymers, Int J. Pharm. 2002 Oct 24; 247(1-2): 57-66, Dorkoosh FA, Verhoef JC, Borchard G, Rafiee-Tehrani M, Verheijden JH, Junginger HE		A
	A41	Abstract, Peroral delivery systems based on superporous hydrogel polymers: release characteristics for the peptide drugs buserelin, octreotide and insulin, Eur J Pharma Sci. 2002 Jun; 15(5): 433-9, Dorkoosh FA, Coos Verhoef J, Ambagts MH, Rafiee-Tehrani M, Borchard G, Junginger HE		A
	A42	Abstract, Development and characterization of a novel peroral peptide drug delivery system. J Control Release. 2001 Apr 28; 71(3): 307-18, Dorkoosh FA, Verhoef JC, Borchard G, Rafiee-Tehrani M, Junginger HE		A

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

**PROPRIETARY MATERIAL NOT OPEN TO PUBLIC.
TO BE OPENED ONLY BY EXAMINER OR OTHER AUTHORIZED
PATENT AND TRADEMARK OFFICE EMPLOYEE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vladimir SABETSKY

Title: ORAL INSULIN COMPOSITION
AND METHODS OF MAKING
AND USING THEREOF

Appl. No.: 10/792,376

Filing Date: 03/04/2004

Examiner: Unassigned

Art Unit: Unassigned

PROPRIETARY INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.56 AND MPEP §§ 724

Commissioner for Patents
P.O. 1450
Alexandria, Virginia 22313-1450

Sir:

The following is a copending U.S. patent application which relates to the above-identified application.

<u>Attorney Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor</u>
028093-0114	10/792,383	3/4/04	Vladimir Sabetsky

Applicant considers the aforementioned document and the disclosure of their existence as pending application to constitute proprietary information. Accompanying this Proprietary Information Disclosure Statement is a transmittal letter indicating that the materials contained herein are proprietary, as required by MPEP § 724.02.

Applicant respectfully requests that the Examiner consider the foregoing information and provide in the next official communication the information set forth in MPEP § 724.04(a), particularly the information under item (D), so that the applicant can, if appropriate, subsequently file a petition to expunge those materials, as provided according to MPEP § 724.05.

Respectfully submitted,

Date 4/21/04

By Leon Radomsky

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Leon Radomsky
Attorney for Applicant
Registration No. 43,445

**PROPRIETARY MATERIAL NOT OPEN TO PUBLIC.
TO BE OPENED ONLY BY EXAMINER OR OTHER AUTHORIZED
PATENT AND TRADEMARK OFFICE EMPLOYEE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vladimir SABETSKY

Title: ORAL INSULIN COMPOSITION
AND METHODS OF MAKING
AND USING THEREOF

Appl. No.: 10/792,376

Filing Date: 03/04/2004

Examiner: Unassigned

Art Unit: Unassigned

**TRANSMITTAL LETTER FOR
PROPRIETARY INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 and M.P.E.P. §§ 724 and 724.02**

Commissioner for Patents
P.O. 1450
Alexandria, Virginia 22313-1450


Sir:

Attached hereto is a Proprietary Information Disclosure Statement submitting proprietary information to the Patent and Trademark Office in accordance with the requirements of 37 C.F.R. § 1.56 and MPEP § 724. Applicants respectfully request that the

information be considered only by the Examiner in charge of the above-caption application,
or other authorized Patent and Trademark Office employee.

Respectfully submitted,

Date 4/21/04

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Leon Radomsky
Attorney for Applicant
Registration No. 43,445